Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy-induced neuropathy.

Anjali Bhagra1, Ravi D Rao

  • 1Department of Oncology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Current Oncology Reports
|June 26, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining key qualities for transformational leadership: LLIFE leadership competencies approach.

BMJ leader·2026
Same author

Role of organizational network analyses to advance workforce inclusion and belonging: a scoping literature review.

Frontiers in psychology·2025
Same author

Enhancing Belonging in Healthcare: A Commentary on Strategies for Organizational Leadership.

Journal of healthcare leadership·2025
Same author

Reflect, Inspire, Strengthen, and Empower 2.0 Program: Advancing Careers and Leadership for Women Physician Staff in an Academic Institution.

Women's health reports (New Rochelle, N.Y.)·2024
Same author

Grace, Inspiration, Fulfillment, Timeless, Soulful (GIFTS): The Why and How of Podcasts for Recognition and Mentoring of Faculty in Medicine.

Journal of primary care & community health·2023
Same author

Addressing racial disparities in surgical care with machine learning.

NPJ digital medicine·2022
Same journal

Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.

Current oncology reports·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
See all related articles

Chemotherapy-induced peripheral neuropathy (CIPN) causes debilitating symptoms and limits cancer treatment. Current therapies offer modest relief, highlighting the need for further research into its causes and effective treatments.

Area of Science:

  • Oncology
  • Neurology
  • Pharmacology

Background:

  • Peripheral neuropathy is a frequent dose-limiting side effect of chemotherapy.
  • Chemotherapy-induced peripheral neuropathy (CIPN) leads to significant symptoms, reduced function, and treatment interruptions.
  • Current treatments for neuropathic symptoms provide only limited efficacy.

Purpose of the Study:

  • To review the challenges and future directions in managing chemotherapy-induced peripheral neuropathy.
  • To emphasize the need for research into CIPN pathogenesis, risk factors, and treatment evaluation.

Main Methods:

  • Review of animal and human studies on CIPN pathogenesis.
  • Discussion of clinical trial design and outcome measurement scales.

Related Experiment Videos

Main Results:

  • CIPN mechanisms are heterogeneous, varying by chemotherapeutic agent.
  • This heterogeneity contributes to the wide range of patient symptoms and treatment responses.
  • Existing analgesic and neurotropic agents show modest effectiveness.

Conclusions:

  • Optimal management of CIPN requires deeper understanding of nerve injury mechanisms.
  • Identifying patient-specific risk factors is crucial for personalized treatment.
  • Development of standardized measurement scales and rigorous clinical trials is essential for evaluating new therapeutic agents.